News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
18,390 Results
Type
Article (570)
Company Profile (4)
Press Release (17816)
Section
Business (9522)
Career Advice (20)
Deals (1368)
Drug Delivery (1)
Drug Development (1316)
Employer Resources (7)
FDA (235)
Job Trends (482)
News (11772)
Policy (464)
Tag
Academia (42)
Allergies (2)
Alliances (675)
ALS (4)
Alzheimer's disease (37)
Antibody-drug conjugate (ADC) (5)
Approvals (242)
Artificial intelligence (10)
Autoimmune disease (1)
Automation (1)
Bankruptcy (9)
Best Places to Work (426)
Biosimilars (2)
Biotechnology (2)
Bladder cancer (3)
Breast cancer (15)
Cancer (96)
Cardiovascular disease (9)
Career advice (17)
CAR-T (4)
Cell therapy (14)
Clinical research (1210)
Collaboration (23)
Compensation (31)
COVID-19 (53)
C-suite (9)
Cystic fibrosis (2)
Data (162)
Depression (6)
Dermatology (2)
Diabetes (15)
Diagnostics (210)
Digital health (2)
Diversity, equity & inclusion (2)
Drug discovery (5)
Drug pricing (1)
Duchenne muscular dystrophy (7)
Earnings (9184)
Employer branding (3)
Employer resources (5)
Events (1434)
Executive appointments (10)
FDA (370)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (1)
Funding (18)
Gene editing (2)
Gene therapy (8)
GLP-1 (18)
Government (56)
Guidances (101)
Healthcare (688)
Huntington's disease (2)
Immunology and inflammation (5)
Immuno-oncology (2)
Indications (5)
Infectious disease (55)
Inflammatory bowel disease (3)
Inflation Reduction Act (1)
Intellectual property (5)
Interviews (2)
IPO (1004)
Job creations (66)
Job search strategy (17)
JPM (1)
Labor market (2)
Layoffs (13)
Legal (72)
Liver cancer (3)
Lung cancer (17)
Lymphoma (6)
Manufacturing (13)
MASH (3)
Medical device (625)
Medtech (628)
Mergers & acquisitions (387)
Metabolic disorders (31)
mRNA (1)
Multiple sclerosis (1)
Neurodegenerative disease (4)
Neuropsychiatric disorders (3)
Neuroscience (67)
NextGen: Class of 2026 (132)
Non-profit (91)
Obesity (10)
Ovarian cancer (5)
Pancreatic cancer (2)
Parkinson's disease (5)
Patents (13)
Patient recruitment (6)
Peanut (2)
People (590)
Pharmaceutical (1)
Phase 1 (268)
Phase 2 (480)
Phase 3 (565)
Pipeline (504)
Postmarket research (36)
Preclinical (91)
Press Release (3)
Prostate cancer (3)
Radiopharmaceuticals (7)
Rare diseases (18)
Real estate (93)
Recruiting (5)
Regulatory (390)
Reports (2)
Research institute (57)
Resumes & cover letters (1)
RNA editing (1)
RSV (1)
Schizophrenia (8)
Series B (1)
Sickle cell disease (7)
Special edition (1)
Spinal muscular atrophy (2)
Startups (37)
Stomach cancer (1)
Supply chain (1)
Vaccines (21)
Venture capital (2)
Weight loss (10)
Women's health (4)
Date
Last 7 days (26)
Last 30 days (115)
Last 365 days (1088)
2026 (299)
2025 (1062)
2024 (1155)
2023 (1484)
2022 (4229)
2021 (1500)
2020 (1418)
2019 (1099)
2018 (920)
2017 (580)
2016 (405)
2015 (650)
2014 (410)
2013 (284)
2012 (324)
2011 (326)
2010 (348)
Location
Africa (13)
Arizona (8)
Arkansas (1)
Asia (1100)
Australia (76)
California (448)
Canada (127)
China (27)
Colorado (33)
Connecticut (15)
Delaware (16)
Europe (2422)
Florida (59)
Georgia (14)
Illinois (31)
India (1)
Indiana (23)
Japan (7)
Kansas (5)
Kentucky (3)
Louisiana (4)
Maine (3)
Maryland (41)
Massachusetts (278)
Michigan (36)
Minnesota (37)
Missouri (4)
Nebraska (2)
Nevada (1)
New Hampshire (5)
New Jersey (130)
New York (94)
North Carolina (45)
Northern California (254)
Ohio (10)
Pennsylvania (74)
South America (37)
South Carolina (1)
Southern California (162)
Tennessee (6)
Texas (62)
United States (1519)
Utah (16)
Virginia (2)
Washington State (38)
Wisconsin (4)
18,390 Results for "260".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
iMDx Announces $26.0 Million Registered Direct Offering
February 11, 2026
·
5 min read
Press Releases
Theolytics Awarded €8 million in Horizon Europe 2025 Grant Funding to Advance Phase 2 Study of THEO-260 in Ovarian Cancer
March 4, 2026
·
5 min read
Press Releases
Theolytics to Present Ongoing Phase I/IIa OCTOPOD-IV Trial of THEO-260 in Ovarian Cancer at ESMO 2025
October 13, 2025
·
4 min read
Press Releases
Tango Therapeutics to Present First Clinical Data from TNG260 at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025
October 6, 2025
·
8 min read
Press Releases
uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE)
May 29, 2025
·
6 min read
Layoffs
Evonik to Lay Off Additional Employees, Cutting up to 260 in Germany
Evonik’s latest layoffs are tied to discontinuing production of keto acids in Hanau, Germany, by the end of next year. Earlier this year, news broke the company is also cutting up to 2,000 employees globally by 2026.
October 14, 2024
·
1 min read
·
Angela Gabriel
Genetown
Apollo Therapeutics Announces Second Close of Series C Financing Bringing Total Raised in Round to $260 Million
Apollo Therapeutics announces that during December 2023 it completed a second close of its Series C financing, raising an additional $33.5 million and bringing the total raised in this round by the Company during 2023 to $260 million.
January 2, 2024
·
3 min read
Press Releases
Theolytics Doses First Patient in Phase I/IIa Trial of THEO-260 in Ovarian Cancer
November 19, 2024
·
4 min read
ReCode Raises $260M in Series B Financing to Advance Lead Programs
Bringing in an additional $50 million in a Series B extension, ReCode Therapeutics’ total haul for the funding round totaled $260 million, which it will use to further its experimental mRNA therapies.
September 20, 2023
·
2 min read
·
Tristan Manalac
Business
Cardurion Raises $260M to Advance Cardiovascular Assets
Backed by Bain Capital, Cardurion Pharmaceuticals will use the Series B funds to advance two assets for heart failure and other cardiovascular conditions.
July 16, 2024
·
1 min read
·
Tyler Patchen
1 of 1,839
Next
